Resource Centre

001 BS Oct 2020

Combatting COVID-19 with real-world evidence

Real-world data has already been collected from millions of patients across the world from electronic medical records, hospital reports, state-wide healthcare utilisation reports, testing centres, insurance claims databases, from patients directly and other real-world sources. Researchers can rapidly analyse these data sets to answer important questions, such as how and why different populations contract the […]

Read More
001 BR Sep 2020

Synapse and FDA collaborate to swiftly generate real-world data (RWD) in COVID-19 patients with cancer

The collaboration is already yielding useful results and aims to tackle the following: Investigating methods to derive RWD from multiple sources including electronic health records, registries and molecular data Enhancing understanding of how patients respond to therapies outside of clinical trials to improve care and outcomes Understanding the impact of COVID-19 on cancer care Click here to learn more […]

Read More
001 LN Aug 2020

Real-world evidence supports CAR-T-cell therapy’s safety and efficacy

A retrospective study in 275 (treated) patients with relapsed or refractory large B-cell lymphoma found (Yescarta) axicabtagene ciloleucel gave similar responses to those seen in clinical trials This evidence is valuable in supporting the clinical trial results; because “The issue with clinical trials is that they often are very highly selective,” – Michael D. Jain, MD, […]

Read More
001 BR August 2020

NICE and Flatiron partner to utilise real-world oncology data in informing decisions about cancer therapy access

Flatiron Health have been partnered with the FDA in the US since 2016, with whom they have explored real-world outcomes and alternative study methods Experts from both NICE and Flatiron Health will conduct research using Flatiron’s electronic health record (EHR)-derived database “We are excited to explore how real-world evidence could be incorporated into our work […]

Read More
001 BR July 2020

COVID-19 pandemic catalyses real-world oncology data uptake

“By necessity, COVID-19 has pushed the cancer clinical trial community out of its comfort zone to rapidly deploy remote assessments and digital health technology, [prompting] unprecedented collaboration to explore the use of real-world data. We cannot lose this opportunity to learn and advance our knowledge of the strengths and limitations of decentralized trials and real-world […]

Read More
001 VN Jul 2020

Real-world evidence (RWE) market worth over £1bn by 2023

Oncology segment accounted for the largest share of the RWE solutions market in 2017 The rising focus on end-to-end RWE services and growth within emerging markets are expected to provide further business opportunities for players operating in the RWE market Click here to learn more About SVMPharma SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence […]

Read More
001 DC July 2020

Adjuvant immunotherapy conferred a 93% survival at 1 year for patients with resectable melanoma at the highest risk of relapse

The analysis captures the first survival data from the National Cancer Database (NCDB) since the FDA’s 2015 approval of ipilimumab (Yervoy) following curative intent surgery in stage III patients. Survival data were available for the 4,094 patients diagnosed in 2015, of which 1,014 were treated with immunotherapy. At 1 year, 93% of patients that received surgery plus […]

Read More
001 FAD COVID 19 June 2020

FDA COVID-19: new real-world evidence data collection

FDA search for evidence based insights from health records for COVID-19 Aetion applies big-data analytics to patients’ electronic health records to evaluate safety and effectiveness for pharmaceutical and biotech companies Real-world data collection from multiple sources The rapid analytics are expected to help FDA better evaluate proposed diagnostics, vaccines, and treatments as the pandemic continues to […]

Read More
001 DC June 2020

Real-world data to combat COVID-19

Monitoring data on hospitals’ utilisation and capacity rates: location and number of licensed beds, staffed beds, ICU beds, and total bed utilisation rates Plan for critical care based on epidemiological data on COVID-19 and clinical outcomes: modelling tools development to identify surges in clinical demand, as well as best- and worst-case scenarios of COVID-19-induced strain on […]

Read More
001 LN Jun 2020

Real-world data is an invaluable supplement to randomised control trials

An article was published recently in the Journal of Clinical Pathways, titled “Real-World Data Will Continue to Provide Real Value to the Drug Development and Commercialization Process” It affirmed that while randomised controlled trials provide the necessary information on drug safety and efficacy, they are often not generalisable to the real-world population; but real-world information […]

Read More
001 BR May 2020

FDA turns to real-world evidence in the fight against COVID-19

“Within the context of COVID-19, we’ve got this urgency to learn what we can as soon as we can, and that means that we need to be learning from the patients that are receiving care right now and trying to understand how do we apply that as quickly as possible” Utilising real-world data (RWD) sources […]

Read More
001 DC May 2020

Real-world evidence (RWE) use to improve oncology cares of tomorrow

Clinical trials are time-consuming, expensive, and not representative of a broad patient population. Additionally, cancers increasingly stratified by molecular subtypes question the exclusive use of these clinical trials for regulatory decision-making. Physicians use a variety of subjective and objective indicators to determine whether a treatment is working,  how you measure “success” in the real world […]

Read More
001 LN May 2020

Real-world facemask performance – harmful or beneficial?

Evidence from controlled settings clearly point to face masks providing disease control benefits because they prevent the disease particles entering the air and prevent infected persons from spreading the disease However, in the real-world, the evidence isn’t as sure; some trials either report non-significant results (erring towards more harmful) or outright more harmful This is […]

Read More
002 AZ LN VN Apr 2020

Baseline UK real-world study in ovarian cancer pre-PARPi published

A study was published recently on the real-world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors as a result of a collaboration between AstraZeneca and SVMPharma The study, aside from providing a baseline for future evaluations to […]

Read More
002 BR Feb 2020

Introduction of e-prescribing in cancer improved safety 10-fold

Electronic prescribing records were introduced as they offer vastly improved communication between different healthcare professionals and patients, which was found to be the source of a high proportion of prescribing errors A study was carried out at St Bartholomew’s Hospital, London to assess whether or not the introduction of electronic prescribing led to improved patient […]

Read More
001 BR Mar 2020

Wearable tech is providing a wealth of untapped real-world data

In the last 20 years, connected digital device use has grown approximately 32% per year, with a huge number of people using smart phones & fitness trackers. Each of these devices is recording current, real-time data Already medical applications are revealing themselves; for example, wearable devices that provide continuous blood glucose testing in diabetic patients […]

Read More
001 LN Mar 2020

NICE formally adopts plan for real-world evidence utilisation

In January, a plan to use a broader range of evidence was formally adopted by NICE By using patient records and real-world evidence (such as registries and clinical audits), NICE anticipate improved guidance and sped-up recommendation updates While this is intended primarily for health and social care system guidance, it may also be extended to health […]

Read More
001 VN March 2020

Favipiravir delivers positive patient outcomes in COVID-19

“Zhang Xinmin, an official at China’s science and technology ministry, said favipiravir, developed by a subsidiary of Fujifilm, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients. Patients who were given the medicine in Shenzhen turned negative for the virus after a median of four days after becoming positive, compared […]

Read More
001 BR Feb 2020

Real-world study shows inconsistency in haemophilia diagnosis rates

Many practitioners are aware that haemophilia is underdiagnosed; a real-world evidence study observed diagnosis rates varying in haemophilia A (16-47%) and haemophilia B (34-65%), showing an unmet need for more accurate and prevalent testing Many patients with haemophilia die before adulthood due to inadequate treatment; even with sufficient treatment, life expectancy in males is approximately […]

Read More
002 LN Feb 2020

NICE to increase use of real-world evidence

NICE plans to use more data resources than RCTs this year for submissions MHRA already takes account of real-world studies, in order to facilitate their upcoming 150 day licensing commitments The utilisation of real world data will be key in tackling the funding and access issue surrounding NICE reimbursement Click here to learn more About SVMPharma SVMPharma […]

Read More
003 BR Feb 2020

Combining RCTs and RWE studies to alter the regulatory approval process

Hybridisation of RCTs and RWE studies reinforce the benefits of both, while reducing the limitations of traditional study formats The potential of real-world data that provides adequate scientific evidence for regulatory decision-making is being realised Innovative study designs must be developed to unlock this potential Click here to learn more About SVMPharma SVMPharma is an innovative strategic […]

Read More
001 LN Feb 2020

Real-world data provides the opportunity to enhance regulatory decisions for new drugs

Real-world data and evidence provide valuable performance data on a post-approval drug to create a comprehensive clinical snapshot This can later support regulatory and reimbursement decisions and clinical guidelines More and more stakeholders in the pharmaceutical pipeline are recognising the value of real-world data Click here to learn more About SVMPharma SVMPharma is an innovative strategic consultancy, […]

Read More
001 VN Feb 2020

Cancer Electronic Prescribing Records – Real-world Data

  Electronic prescribing records, or EPRs, are a rich untapped source of real-world evidence SVMPharma’s unique EPR real-world studies are one step ahead of the Systemic Anti-Cancer Therapy (SACT) data set Click here to learn more About SVMPharma SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma […]

Read More
006 Mailing  infograhic-SVM 2.0

Largest UK Real-world Evidence study in advanced NSCLC

To the best of the authors’ knowledge, this is the first large-scale, real-world UK study of its kind in this patient population The study cohort accounts for approximately 10% of the total adult first-line treated advanced non-small cell lung cancer population in the UK Electronic prescribing records (EPRs) were the primary data source used in […]

Read More
RWE76 - RCTs finally look beyond RECIST

RCTs finally look beyond RECIST: Treatment beyond first RECIST-defined progression

Post-hoc analysis on an atezolizumab RCT study used treatment beyond first RECIST This endpoint means that RCTs are moving towards being more aligned with real-world evidence studies, which often use TTD Click here and here to read the source articles About SVMPharma SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical […]

Read More
RWE75 - RWE supports efficacy of and shows lower toxicity in Kymriah CAR-T Therapy

Real-world evidence supports efficacy of and shows lower toxicity in Kymriah CAR-T Therapy

Two studies looking at patients with diffuse large B cell lymphoma (DLBCL) and acute lymphoblastic leukaemia (ALL) were presented at ASH, looking at Novartis’ CAR-T therapy, Kymriah (tisagenlecleucel). Both studies supported the pre-regulatory approval clinical trials data, with Kymriah achieving high response rates, and in fact saw fewer serious side effects, such as neurotoxicity. This […]

Read More
RWE74 - Real-world data shows drugs’ benefits at ASH 2019

Real-world data shows drugs’ benefits at ASH 2019

Eliquis, Adynovate and Feiba were presented in last month’s ASH 2019 meeting as the subject of studies which showed their benefits through the use of real-world data. Results focused on cost-effectiveness, safety, outcomes and benefits. “Real-world evidence plays a crucial role in understanding patterns of care that happen in day-to-day medical practice outside of rigorous […]

Read More
RWE73 - Largest UK RWE Study of Sequenced 2nd generation TKIs in CML

Largest UK RWE Study of Sequenced 2nd Generation TKIs in CML

This weekend at the 61st American Society of Haematology Annual Meeting and Exposition in Orlando, Florida, SVMPharma and Incyte’s study on chronic myeloid leukaemia (CML) was presented as a poster. This study was the largest UK real world evidence study in CML patients who had been sequenced to a 3rd line tyrosine kinase inhibitor (TKI) […]

Read More
RWE72 - Real World Evidence Driving Decision Making in Oncology

Real World Evidence: Driving Decision Making in Oncology

Oncology prescribing practices rely heavily on the data from clinical trials. However, due to lesser patient numbers found in clinical trials, knowledge gaps start presenting themselves in the form of understanding disease progression, overall survival, efficacy etc. Information like this can be collected in real world evidence studies so that more personalised treatment pathways can […]

Read More
RWE71 - Real-world Evidence Allows for Customised and Precise Treatment

Real-world Evidence Allows for Customised and Precise Treatment

New data and technology can drive tailored treatments through physician education Real-world evidence shows comparative effectiveness, which is valuable when determining the ideal patient management scheme “A randomized clinical trial is trying to show efficacy. It asks, how well does this work under optimal circumstances? In contrast, a real-world evidence study is trying to show […]

Read More
019 RWE Ideas Nov 2019

RCT Vs Real World Evidence

RCTs primarily generate efficacy; complement them with real-world evidence studies to generate effectiveness. Find out if a drug works in a real-life setting, with real patients. Determine when, how often and why a drug is used in a prescribing line. Retrospectively review patients for long periods of time. About SVMPharma SVMPharma is an innovative strategic […]

Read More
018b RWE Ideas Oct 2019

150,000 patient RWE study initiated to evaluate Cologuard

Colorectal cancer, the second highest cancer killer in the US, can be detected by Cologuard; which has been shown to be 92% sensitive to colorectal cancer and 62% sensitive to high-risk pre-cancer patients. Cologuard is the only at-home colorectal cancer screening test approved by the FDA, and yet approximately 40% of the eligible patients aren’t […]

Read More
RWE68 - Social Media Platforms a Direct-to-Patient RWD Route

Social Media Platforms: a Direct-to-Patient RWD Route

Patient focused care can only truly be supported with an empathetic perspective on patient experience. RWD  is typically utilised in reviewing clinical endpoints, however, it could be used for patient reported outcomes, and this is vital to a more holistic view of the disease area and its impact. Social media could be the gateway into […]

Read More
RWE - 67 ISPOR on RWD Advantages

ISPOR on RWD Advantages

Rapid and effective data generation increases value for the study sponsor. Larger groups allow for longitudinally tracking of patient cohorts and sub-population analyses Real world studies demonstrate real-world practices and behaviours. SVMPharma, driving the outcomes that matter with RWE studies leading to positive HTA submissions and value based outcomes. Why be limited with small study populations, […]

Read More
RWE66 NICE hints at the greater use of data analytics and real-world evidence

NICE hints at the greater use of ‘data analytics and real-world evidence’

A review on NICE’s HTA methodologies has been released, including review on quality of life measures NICE acknowledges the greater use of ‘data analytics and real-world evidence’ could play a part in how it might revise its methodologies. The aim is to support faster access to new technologies for patients Click here to read the source article […]

Read More
018a RWE Ideas Oct 2019

Real-World Data Reveals Improved Durability Results Missed in IBD RCTs

Increased time-to-treatment-failure was revealed in a real world study on tofacitinib’s effectiveness The study allowed patients who wouldn’t have been considered for RCT inclusion to be analysed “This underscores the potential for real-world evidence studies to uncover new evidence of efficacy that might have been missed by the original controlled trials.” – Vivek Rudrapatna, University of California San Francisco […]

Read More
Working Together is Essential to Release the Full Potential of Real World Evidence

Working Together is Essential to Release the Full Potential of Real World Evidence

Data can come from hospitals, patients, their family, government initiations, analytics companies, and a myriad of other potential partners For robustness, real-world data should come from several sources, allowing it to be translated into evidence to support other projects Coordinated co-operation is key to cover as many data sources as possible to fully utilise real-world […]

Read More
RWE63 - RCT Snapshot vs. Real World Evidence treatment pathway

RCT snapshots vs. Real World Evidence treatment pathway

RWE can provide insight on an entire treatment pathway, whereas an RCT can typically only focus on a single line. This  evidence may be used to: aid in the refinement of patient care and clinical pathway design overcome data gaps inform clinical decision-making support RCT data in licensing and market authorisation applications Click here to find out more […]

Read More

RWD Shows Treatment Effectiveness with 30,000 Patients

Swedish researchers investigated whether there were any clinically meaningful differences between anti-psychotic medications’ effectiveness in treating schizophrenia A RWD database was used to carry out the nationwide study RWE allowed the study to find the treatments most likely to prevent relapses Click here to see the source article    About SVMPharma SVMPharma is an innovative strategic consultancy, specialising in […]

Read More
RWE61 - Oncology Electronic Prescribing Records Chart Note study

Oncology RWE – Electronic Prescribing Records Chart Note Study

RWE Oncology Electronic Prescribing Records provide a unique opportunity to conduct large scale chart note reviews within all NHS hospitals in the UK SVMPharma Oncology Electronic Prescribing Records Chart notes have studied more than 6,000 patients in multiple tumour sites (prostate cancer, renal cell carcinoma, ovarian cancer, and lung cancer) Oncology Electronic Prescribing Records provide […]

Read More

Real World Evidence can define treatment information

RWE provides many useful insights, and is currently being used primarily for RCT evidence supplementation ” …it’s clear that real-world data will play an increasingly important role in how drugs are assessed in the future.”“Industry, academia and the public sector will all have to work together to make this a real priority.” – Dr Linda […]

Read More
RWE59 - Do RWE results match those from RCTs

Do RWE results match those from RCTs?

A pilot study led by Friends of Cancer Research (Friends) investigated how real world evidence (RWE) compares to the results from randomised clinical trials (RCTs) (for advanced non-small cell lung cancer). The study showed consistency between RWE and RCTs, emphasising their potential for supporting clinical decision-making “RWE is an important tool for continued learning about treatment outcomes […]

Read More

Real World Evidence shows impact of HPV vaccines on cervical cancer

A systematic review and meta-analysis has shown strong evidence of the effectiveness of the HPV vaccine “Our results can be used by clinicians to illustrate the real-world impact of HPV vaccination outside the very controlled settings of randomized trials.” – Marc Brisson, PhD (Université Laval, Quebec, Canada) “…it was interesting that the promising HPV vaccine efficacy […]

Read More

FDA’s INFORMED science and technology incubator, to bring real world data to the development of breast cancer treatment

In 332,630 new cases of breast cancer, only 3% – 5% of patients participated in traditional clinical studies. RWE: “expected to allow for deeper insights and greater understanding of the variance of patient treatment outcomes” An initial two year contract focused on breast cancer, but there’s potential to explore other cancer epidemiology Click here to see the source article    About SVMPharma […]

Read More

Why sample size matters

1000 patient record study with Cancer Electronic Prescribing Records (EPRs), the data source for SACT. RWE to be used in improving patient care. Click here to see the source article    About SVMPharma SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online […]

Read More

FDA encourages RWE in oncology

RWE can provide deep and accurate real-world clinical evidence, providing useful data for the increasingly stratified molecular subtypes of cancer “When we enable oncologists to see patient data clearly, we can make sure that everyone touched by cancer finds the right path to the right care.” Click here to see the source article    About SVMPharma SVMPharma is an […]

Read More

RWE highlights treatment gaps in Major Depressive Disorder patients

“Data Presented at the American Psychiatric Association 2019 Meeting Suggest a Low Rate of Psychiatric Care Received by Adult Patients with MDD Before Suicide Ideation or Attempt Diagnosis” “Additional Data Show Patients Have a High Risk of Hospital Readmission or Subsequent Emergency Department Visit after Suicide Ideation or Attempt” Click here to see the source article  About SVMPharma SVMPharma […]

Read More

Leveraging RWD to improve regulatory decisions

How real world evidence was used to support approval of Ibrance for male breast cancer “Leveraging RWD to improve regulatory decisions is a key strategic priority for the FDA. This data may be derived from a variety of sources, such as electronic health records, medical claims, product and disease registries, laboratory test results and even […]

Read More

In the era of cell and gene therapy, how robust is RWE collection?

  “Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching” “Existing data collection infrastructure in indications with potential cell or gene therapies launches in the next five years in the UK is overall not sufficient to facilitate outcomes-based reimbursement.” Click here to see the source article  Reference Jørgensen, J., […]

Read More

RWE improving asthma outcomes

5.4 million people in the UK are currently affected by asthma 3 three year projects will be taking place in Manchester, Edinburgh and Portsmouth respectively Each project set to receive more than £200,000 from innovate and Asthma UK Click here to see the source article  Reference GOV.UK. (2019). Better, faster, more personalised asthma treatment. [online] Available at: https://www.gov.uk/government/news/better-faster-more-personalised-asthma-treatment [Accessed 28 […]

Read More

RCT outcomes predicted by RWE

FDA and Brigham and Women’s Hospital have expanded their previous RCT DUPLICATE demonstration project to predict the results of seven Phase IV trails that are currently ongoing Part of the project will estimate the results of randomised controlled trials before they are finished with the use of RWE Click here to see the source article  Reference Hale, C. (2019). Using […]

Read More

RWE can accelerate the pace of discovery of new oncology therapies

Companies and HTA bodies are looking at real-world evidence to inform reimbursement of novel cancer therapies like CAR-T Click here to see the source article  Reference Be The Match BioTherapies. (2019). CIBMTR to Track Long-Term Outcomes Data for Kymriah®. [online] Available at: https://bethematchbiotherapies.com/newsroom/cibmtr-to-track-long-term-outcomes-data-for-kymriah/ [Accessed 23 Apr. 2019].   About SVMPharma SVMPharma is an innovative strategic consultancy, specialising in Real World […]

Read More

RWE Challenges and Misconceptions

A look into the 5 common myths for the adaption of patient-reported RWE for devices, these include Age as a barrier to technology HCP reluctance to adopting new technology Sharing of health data Clinical trial compliance The readiness of device platforms Click here to see the source article  Reference Hellman B. Real-World-Evidence Mythbusting: 5 myths holding back patient-reported RWE […]

Read More

Digitalisation of health records leveraging RWE

“It’s getting more expensive to do traditional clinical trial research, so industry is looking at ways it can achieve similar goals using routinely collected data,” said Paul Taylor, a health informatics expert at University College London. “As the breadth and reliability of RWE increases, so do opportunities for FDA to also make use of this […]

Read More

European regulators are looking at RWE for HTA

Two ongoing Horizon 2020 projects, COMED and IMPACT-HTA, will provide methodological guidance on how to use RWD for health economic evaluation, where COMED will be focusing more on medical devices and IMPACT-HTA on economic evaluation in the context of HTA Click here to see the source material Reference Comedh2020.eu. (2019). Home. [online] Available at: http://www.comedh2020.eu/wps/wcm/connect/Site/COMED/Home [Accessed 5 Mar. 2019]. […]

Read More

50% of real-world studies started in the last 3 years

Half of the world’s 1,800 clinical studies involving real-world or real-life data since 2006 have been started in the last three years (from 2015-2018), according to a Reuters analysis of the U.S. National Institutes of Health’s clinicaltrials.gov website Studying real-world evidence offers manufacturers a powerful tool to prove the value of their drug Hot areas […]

Read More

DESERVE showed significant benefits in NHS healthcare savings

SVMPharma’s real-world evidence helped deliver a real-world study looking at the clinical outcomes of triptorelin vs other LHRH agonists (LHRHa) in clinical practice for prostate cancer patients. Our real-world evidence helped show a significant reduction in healthcare resource utilisation for the NHS as well as maintenance in PSA control (a biomarker in prostate cancer) when switching to a 6-monthly formulation […]

Read More
FINAL RWE38 ICE-PT

A retrospective cohort study of the clinical outcomes of ILUVIEN in four ophthalmology centres in Portugal (ICEPT)

SVMPharma’s real-world evidence helped deliver a unique real-world multicentre study in Portugal (ICEPT) looking at the clinical outcomes of fluocinolone acetonide implant (ILUVIEN®) in clinical practice for diabetic macular oedema (DMO) patients. Our real-world evidence provided valuable insights and helped show a marked reduction in odema in 66% of DMO patients’ eyes (n=75) in real-world clinical practice.   A retrospective cohort study […]

Read More
FINAL RWE36 ICE infographic

SVMPharma’s real-world studies in diabetic eye oedema led to multiple successful publications and congress presentations in the UK and Europe

SVMPharma has recently collected real-world data in the UK and Europe for which has lead to successful outcomes from publications to presentations in a major European congress Click on the references below to find out more References (1) Currie CJ. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular […]

Read More
FINAL RWE37 CF infographic

First real-world multicentre study of the use of inhaled aztreonam lysine in clinical practice

SVMPharma’s Real World Treatment Evaluator tool helped deliver the first real-world multicentre study of the use of inhaled aztreonam lysine in clinical practice for cystic fibrosis (CF) patients. Our treatment evaluator tool provided valuable insights and demonstrated significant improvement in lung function in CF patients in a real-world setting.   A treatment evaluator tool to monitor the […]

Read More
FINAL_RWE infographic 30

Answering real world clinical questions with Real World Data

Click here or the image below to find out more Keywords: Real World Evidence, Real World Data, Retrospective, Prospective, Rapid outcomes, Clinical outcomes, Clinical Insights, Health Technology Assessment, The National Institute for Health and Care Excellence, NICE, Data Gaps, Post-Approval  

Read More
FINAL_RWE infographic 29

97% of Companies to Increase Use of Real World Patient Data

Click here or the image below to find out more Keywords: Real World Evidence, Real World Data, Retrospective, Prospective, Rapid outcomes, Clinical outcomes, Clinical Insights, Health Technology Assessment, The National Institute for Health and Care Excellence, NICE, Data Gaps, Post-Approval  

Read More
FINAL_RWE infographic 27

Who are the Real World Evidence Stakeholders?

Click here or the image below to find out more Keywords: Real World Evidence, Real World Data, Retrospective, Prospective, Rapid outcomes, Clinical outcomes, Clinical Insights, Health Technology Assessment, The National Institute for Health and Care Excellence, NICE, Data Gaps, Post-Approval  

Read More
004_FINAL_RWE infographic 26

NICE leads access to medical devices

Click here or the image below to find out more   Keywords:  Medical Device, FDA, Real World Evidence, Real World Data, Retrospective, Prospective, Rapid outcomes, Clinical outcomes, Clinical Insights, Health technology assessment, The National Institute for Health and Care Excellence, NICE, Data Gaps, Post-Approval

Read More
005_FINAL_A27

Turning Real World Data into Real World Evidence: identifying and overcoming RCT data gaps

Click here or the image below to find out more   Keywords:  SACT, Systemic Anti-Cancer Therapy, Oncology, Electronic Prescribing Records, Real World Evidence, Real World Data, Retrospective, Prospective, Overall Survival, Progression Free Survival, Response rates, Rapid outcomes, Treatment pathways, Clinical outcomes, Line of therapy and cycles, Clinical Insights, Health technology assessment, The National Institute for Health and Care Excellence, NICE, RCT, Registration Studies, Data […]

Read More
FINAL_RWE infographic 25

RWD and RWE: Where is the Value?

Click here or the image below to find out more Keywords:  SACT, Systemic Anti-Cancer Therapy, Oncology, Electronic Prescribing Records, Real World Evidence, Real World Data, Retrospective, Prospective, Overall Survival, Progression Free Survival, Response rates, Rapid outcomes, Treatment pathways, Clinical outcomes, Line of therapy and cycles, Clinical Insights, Health technology assessment, The National Institute for Health and Care Excellence, NICE, Resource implications, Payer communication

Read More
FINAL_RWE infographic 24

30% oncology NICE submissions not recommended

Click here or the image below to find out more Keywords:  SACT, Systemic Anti-Cancer Therapy, Oncology, Electronic Prescribing Records, Real World Evidence, Real World Data, Retrospective, Prospective, Overall Survival, Progression Free Survival, Response rates, Rapid outcomes, Treatment pathways, Clinical outcomes, Line of therapy and cycles, Clinical Insights, Health technology assessment, The National Institute for Health and Care Excellence, NICE

Read More
FINAL_SVMPharma oncology electronic prescribing_reviewed 18-09-2017

SACT vs. Oncology Electronic Prescribing Records

Click here or the image below to find out more Keywords:  SACT, Systemic Anti-Cancer Therapy, Oncology, Electronic Prescribing Records, Real World Evidence, Real World Data, Retrospective, Prospective, Overall Survival, Progression Free Survival, Response rates, Rapid outcomes, Treatment pathways, Clinical outcomes, Line of therapy and cycles, Clinical Insights

Read More
003_RWE 2 Infographic Layout-1

eyeforpharma EU Summit 2016: RWE survey results

75% of industry professionals polled at the efp EU Summit 2016 said internal and external barriers were among the top reasons stopping them from doing RWE projects. Find out more in our survey results below For more on the eyeforpharma EU Summit and RWE, see our presentation by clicking here    

Read More